UMBELLATINE
HELICOBACTER PYLORI INFECTIONS
Nanjing First Hospital, Nanjing Medical UniversitySmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
1 Active assets in the HELICOBACTER PYLORI INFECTIONS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bifidobacterium tetravaccae Nanjing First Hospital, Nanjing Medical University | Phase 4 | BB |
Clarithromycin University of California, Los Angeles | Phase 3 | B |
Amoxicillin University of California, Los Angeles | Phase 3 | B |
Omeprazole University of California, Los Angeles | Phase 3 | B |
Same molecule, other indications
UMBELLATINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →